Tirzepatide dose individualisation: what the evidence actually supports

What did @medicalupdateonline actually say?

The creator described tirzepatide's six available doses, from 2.5mg up to 15mg, and said most of their clients sit at 5mg or 7.5mg, achieving "3 to 4 kilograms of weight loss a month." They also noted that some clients show "very little efficacy, even at 10 milligrams" and need to reach 15mg before results click in. The framing is clinical and experience-based rather than promotional, which is a reasonable starting point. The core message is that response varies between individuals and that dose escalation is not always necessary to achieve meaningful results.

Worth noting: the creator calls the drug "Tezepotide" rather than tirzepatide, and refers to the brand as "Manjaro" instead of Mounjaro. These are likely slip-of-the-tongue errors rather than deliberate misnaming, but in a health context those details matter.

Does the science back this up?

Broadly, yes. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) is the landmark reference here. It tested 5mg, 10mg, and 15mg doses of tirzepatide against placebo in adults with obesity. At 72 weeks, weight loss was 15%, 19.5%, and 20.9% respectively, meaning the dose-response relationship is real but not always dramatic between adjacent doses.

The claim that clients achieve "3 to 4 kilograms of weight loss a month" is plausible during early active weight loss phases, but it is not a reliable average across the full treatment period. SURMOUNT-1 participants lost weight over roughly 72 weeks, meaning monthly averages would be considerably lower when calculated across the whole duration. The creator is likely describing an observation window, not a sustained rate, but that distinction is missing from the video.

The observation that efficacy "clicks in" at different doses for different people aligns with pharmacodynamic variability data. Tirzepatide acts on both GIP and GLP-1 receptors, and receptor sensitivity varies across individuals. This is not a controversial claim.

What did they get wrong (or right)?

Let's give credit where it is due. The dose range is accurate. Tirzepatide is approved in doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, exactly as the creator states. The principle of dose individualisation is well-supported. Framing the 2.5mg starting dose as an escalation step rather than a therapeutic target is also consistent with prescribing guidance.

What is less defensible is the "3 to 4 kilograms a month" figure presented without qualification. That rate would equate to roughly 36 to 48 kilograms per year, which is not consistent with trial data for any approved dose. SURMOUNT-1 showed a mean loss of around 22.5kg at the highest dose over 72 weeks. The creator may be describing early responders or a specific observation window, but stating it without context could set unrealistic expectations for patients.

The mispronunciation of both the drug name and brand name is a minor but real issue on a health platform where viewers may be searching for information.

What should you actually know?

Tirzepatide dose escalation is a legitimate clinical strategy, and the evidence supports individual variation in response. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) confirmed that sustained use at maximally tolerated doses is associated with continued weight loss, and that stopping the medication leads to weight regain. This supports the creator's implicit point that finding the right dose matters for long-term outcomes.

However, dose decisions should be made with a licensed prescriber based on tolerability, response, and medical history. The idea that there is a dose where efficacy "clicks in" is a useful clinical heuristic, but it should not translate into patients self-escalating or pressuring prescribers to jump doses. Side effect burden, particularly gastrointestinal effects, increases with dose in some patients (Davies et al., 2022, The Lancet). Slower escalation is sometimes the right call even when weight loss feels stalled.

• Tirzepatide has six approved dose levels from 2.5mg to 15mg.
• Trial data shows meaningful weight loss at 5mg, with incremental gains at higher doses.
• Individual response variability is real and supported by pharmacological evidence.
• Monthly weight loss rates vary widely and should not be used as a fixed benchmark.